GSK plc (GSK)

GSK plc is a British multinational pharmaceutical and biotechnology company (formerly GlaxoSmithKline) headquartered in London, employing approximately 65,000 people with a market capitalization of roughly $101.7 billion and a share price near $50.67. The company carries a broad, diversified pipeline spanning vaccines, respiratory, infectious disease, oncology, and metabolic indications, with multiple Phase 2 and Phase 3 catalysts expected through H1 2027. Near-term attention centers on readouts for GSK5784283, a Flu mRNA formulation, GSK4527226, Cobolimab, Momelotinib, Dostarlimab, Niraparib, and an adjuvanted RSVPreF3 vaccine, all estimated in the July 2026–January 2027 window.